FDA approves first therapy to treat patients with rare blood disorder - FDA Press Releases

FDA grants approval to Reblozyl (luspatercept–aamt) for the treatment of anemia in adult patients with beta thalassemia who require regular red-blood cell transfusions.

from FDA Press Releases RSS Feed https://ift.tt/32uR7CE
via IFTTT